- 移动端
深圳欣博盛生物科技有限公司品牌商
16 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0
- 0
- 2
- 2
全部产品
- 查看全部分类
- 欣博盛ELISA 试剂盒
- Vectorlabs
- GeneTex
- Peprotech
- Invivogen
- BioXcell
- FuGENE
- Prozyme
- Cayman
- Mirusbio
- ENZO(Alexis, Biomol, Assaydesign&stressgen)
- AbD Serotec
- Surmodics
- Millipore
- Metasystems
- Mabtech
- Proimmune
- Adipogen
- Bioporto
- Southern Biotech (SBA)
- Everest Biotech
- Chondrex
- IQ Products
- Atlas
- Detroit R&D
- StressMarq
- Cell Biolabs
- StrigoLab
- Synaptic Systems
- BioInnovatise
- Cosmo Bio
- Abwiz Bio
- Gerbu
- 蛋白
- 试剂类
- 抗体
- 分子化合物
- Cargille
- Antagen
- Nanoprobes
- Funakoshi
- Demeditec
- Enzo
- Fitzgerald
- Biovendor
- ICL
- Matreya
- PhaRNA
- Funakoshi
- Promise Advanced Proteomics
- Bioassay works
- NSJ Bio
- Aldevron
- CalBioreagents
- 3Helix
- 自产试剂盒
- TriLink
- Virostat
- Agilent
- Epicypher
- Jackson ImmunoResearch
推荐产品
公司新闻/正文
BioXCell new文献引用
563 人阅读发布时间：2020-08-06 15:03
Nature Communications new 发布的文献 ”Contrast-enhanced ultrasound with sub-micron sized contrast agents detects insulitis in mouse models of type1 diabetes” 使用了BioXCell的InVivoPlus anti-mouse CD4(Clone: GK1.5)抗体, 揭示了使用亚微米级造影剂的超声造影检测I型糖尿病小鼠模型中的胰岛素炎。
摘要：In type1 diabetes (T1D) autoreactive T-cells infiltrate the islets of Langerhans, depleting insulin-secreting β-cells (insulitis). Insulitis arises during an asymptomatic phase, prior to clinical diagnosis of T1D. Methods to diagnose insulitis and β-cell mass changes during this asymptomatic phase are limited, precluding early therapeutic intervention. During T1D the islet microvasculature increases permeability, allowing nanoparticles to access the microenvironment. Contrast enhanced ultrasound (CEUS) uses shell-stabilized gas bubbles to provide acoustic backscatter in vasculature. Here, we report that sub-micron sized ‘nanobubble’ ultrasound contrast agents can be used to measure increased islet microvasculature permeability and indicate asymptomatic T1D. Through CEUS and histological analysis, pre-clinical models of T1D show accumulation of nanobubbles specifically within pancreatic islets, correlating with insulitis. Importantly, accumulation is detected early in disease progression and decreases with successful therapeutic intervention. Thus, sub-micron sized nanobubble ultrasound contrast agents provide a predicative marker for disease progression and therapeutic reversal early in asymptomatic T1D.
文章链接：https://www.nature.com/articles/s41467-020-15957-8
订购详情：
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net
摘要：In type1 diabetes (T1D) autoreactive T-cells infiltrate the islets of Langerhans, depleting insulin-secreting β-cells (insulitis). Insulitis arises during an asymptomatic phase, prior to clinical diagnosis of T1D. Methods to diagnose insulitis and β-cell mass changes during this asymptomatic phase are limited, precluding early therapeutic intervention. During T1D the islet microvasculature increases permeability, allowing nanoparticles to access the microenvironment. Contrast enhanced ultrasound (CEUS) uses shell-stabilized gas bubbles to provide acoustic backscatter in vasculature. Here, we report that sub-micron sized ‘nanobubble’ ultrasound contrast agents can be used to measure increased islet microvasculature permeability and indicate asymptomatic T1D. Through CEUS and histological analysis, pre-clinical models of T1D show accumulation of nanobubbles specifically within pancreatic islets, correlating with insulitis. Importantly, accumulation is detected early in disease progression and decreases with successful therapeutic intervention. Thus, sub-micron sized nanobubble ultrasound contrast agents provide a predicative marker for disease progression and therapeutic reversal early in asymptomatic T1D.
文章链接：https://www.nature.com/articles/s41467-020-15957-8
订购详情：
| 产品名称 | 货号 | 规格 |
| InVivoMAb anti-mouse CD4 | BE0003-1 | 1/5/25/50/100mg |
| InVivoPlus anti-mouse CD4 | BP0003-1 | 1/5/25/50/100mg |
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net